Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 4 days ago

Nasus Pharma Ltd: BALYASNY ASSET MANAGEMENT L.P. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Balyasny Asset Management L.P. amended its Schedule 13G stake filing for Nasus Pharma Ltd, disclosing the change under SEC accession number 0001172661-26-005053. The filing updates the asset manager's previously reported position in the pharmaceutical company. Schedule 13G amendments are typically filed by institutional investors whose holdings shift, though the filing summary did not specify the revised share count or percentage. Investors will watch for the detailed ownership figures in the amended document to gauge Balyasny's current exposure to Nasus Pharma.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Balyasny Asset Management L.P., Nasus Pharma Ltd